Literature DB >> 11602840

Rapamycin: clinical results and future opportunities.

B D Kahan1, J S Camardo.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11602840     DOI： 10.1097/00007890-200110150-00001

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  32 in total

Review 1.  Immunotherapy of systemic sclerosis.

Authors:  Rebecca Manno; Francesco Boin
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

2.  Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1.

Authors:  Shuyu Wang; Zhi-Yang Tsun; Rachel L Wolfson; Kuang Shen; Gregory A Wyant; Molly E Plovanich; Elizabeth D Yuan; Tony D Jones; Lynne Chantranupong; William Comb; Tim Wang; Liron Bar-Peled; Roberto Zoncu; Christoph Straub; Choah Kim; Jiwon Park; Bernardo L Sabatini; David M Sabatini
Journal:  Science       Date:  2015-01-07       Impact factor: 47.728

3.  IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells.

Authors:  Heth R Turnquist; Tina L Sumpter; Allan Tsung; Alan F Zahorchak; Atsunori Nakao; Gerard J Nau; Foo Y Liew; David A Geller; Angus W Thomson
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

4.  Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.

Authors:  Tien-I Karleen Su; Dinesh Khanna; Daniel E Furst; Gabriel Danovitch; Christina Burger; Paul Maranian; Philip J Clements
Journal:  Arthritis Rheum       Date:  2009-12

Review 5.  Nanomedicines in renal transplant rejection--focus on sirolimus.

Authors:  Li-Jiuan Shen; Fe-Lin Lin Wu
Journal:  Int J Nanomedicine       Date:  2007

6.  Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.

Authors:  Nousheen Samad; Anas Younes
Journal:  Onco Targets Ther       Date:  2010-09-07       Impact factor: 4.147

7.  Regulation of alloimmune Th1 responses by the cyclin-dependent kinase inhibitor p21 following transplantation.

Authors:  Theodore H Welling; Guanyi Lu; Keri Csencsits; Sherri C Wood; Lamis Jarvinen; D Keith Bishop
Journal:  Surgery       Date:  2007-12-21       Impact factor: 3.982

8.  Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1.

Authors:  A Heredia; A Amoroso; C Davis; N Le; E Reardon; J K Dominique; E Klingebiel; R C Gallo; R R Redfield
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-12       Impact factor: 11.205

Review 9.  The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.

Authors:  Kamalesh Sankhala; Alain Mita; Kevin Kelly; Devalingam Mahalingam; Francis Giles; Monica Mita
Journal:  Target Oncol       Date:  2009-04-21       Impact factor: 4.493

Review 10.  Calcineurin inhibitors in renal transplantation: what is the best option?

Authors:  Kazunari Tanabe
Journal:  Drugs       Date:  2003       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.